Aptevo Therapeutics Inc (APVO)

$1.39 +0.01 (0.72%)
Market Cap 21.40M
Revenue (ttm) 0.00
Net Income (ttm) -24.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 528,400
Avg Vol 2,345,510
Day's Range N/A - N/A
Shares Out 16.85M
Stochastic %K 89%
Beta 1.41
Analysts Sell
Price Target $21.00

Company Profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 838 0500
Fax: 206 838 0503
Address:
2401 4th Avenue, Suite 1050, Seattle, United States
Traildog19
Traildog19 Dec. 5 at 2:57 AM
$APVO
0 · Reply
th3_fail_k1ng
th3_fail_k1ng Dec. 5 at 12:47 AM
$APVO
0 · Reply
_MANDALORIAN_
_MANDALORIAN_ Dec. 5 at 12:01 AM
$APVO didnt i tell you THIS under 1.1x WAS GOLD?
0 · Reply
ParabolicUptrends
ParabolicUptrends Dec. 4 at 8:52 PM
Micro float SNSE is getting a lot of attention! Could be the next crazy runner! Never chase those big runners that are up 100%+ .. Easy way to lose! Key is to buy early before the runs happen! 💎 These tiny float tickers are running 100-400% recently! SNSE starting to get discovered and trending on Stocktwits! Only 500k shares outstanding - keep it on watch bulls! $LASE $APVO $PBM $RAYA now
0 · Reply
Icansee
Icansee Dec. 4 at 8:49 PM
$APVO
0 · Reply
pandapanic
pandapanic Dec. 4 at 6:38 PM
$APVO soon 😁😁
0 · Reply
Felixii
Felixii Dec. 4 at 3:40 PM
$APVO
0 · Reply
hegdaom
hegdaom Dec. 4 at 2:33 AM
$CAPR $APVO
0 · Reply
DonZulu
DonZulu Dec. 4 at 2:21 AM
$CAPR $APVO My winners
0 · Reply
pandapanic
pandapanic Dec. 3 at 9:26 PM
$APVO for those who keep asking
0 · Reply
Latest News on APVO
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Nov 10, 2025, 8:05 AM EST - 24 days ago

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Nov 6, 2025, 8:05 AM EST - 4 weeks ago

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

Oct 8, 2025, 8:20 AM EDT - 2 months ago

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Sep 16, 2025, 8:30 AM EDT - 2 months ago

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Sep 4, 2025, 8:45 AM EDT - 3 months ago

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aug 13, 2025, 8:05 AM EDT - 4 months ago

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Aug 11, 2025, 8:05 AM EDT - 4 months ago

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2025, 11:30 AM EDT - 5 months ago

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Jun 20, 2025, 8:55 AM EDT - 5 months ago

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Jun 20, 2025, 8:01 AM EDT - 5 months ago

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

SWBI

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Jun 18, 2025, 1:34 PM EDT - 6 months ago

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Jun 18, 2025, 11:37 AM EDT - 6 months ago

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2025, 10:52 AM EDT - 6 months ago

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Jun 18, 2025, 8:01 AM EDT - 6 months ago

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Aptevo Participating in the BIO International Convention

Jun 13, 2025, 8:05 AM EDT - 6 months ago

Aptevo Participating in the BIO International Convention

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 22, 2025, 8:05 AM EDT - 7 months ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

May 15, 2025, 8:05 AM EDT - 7 months ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

May 8, 2025, 8:45 AM EDT - 7 months ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 22, 2025, 4:05 PM EDT - 8 months ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 21, 2025, 2:40 PM EDT - 8 months ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 4, 2025, 4:05 PM EDT - 8 months ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 3, 2025, 8:50 AM EDT - 8 months ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Mar 20, 2025, 8:35 AM EDT - 9 months ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Mar 18, 2025, 8:05 AM EDT - 9 months ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Aptevo to Participate in March Conferences

Mar 6, 2025, 8:00 AM EST - 9 months ago

Aptevo to Participate in March Conferences

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 15, 2025, 6:59 PM EST - 10 months ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Feb 14, 2025, 8:05 AM EST - 10 months ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Jan 15, 2025, 8:00 AM EST - 11 months ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Dec 12, 2024, 12:50 PM EST - 1 year ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Dec 12, 2024, 9:00 AM EST - 1 year ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Dec 4, 2024, 8:35 AM EST - 1 year ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 29, 2024, 9:55 AM EST - 1 year ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Nov 26, 2024, 8:35 AM EST - 1 year ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Nov 22, 2024, 8:35 AM EST - 1 year ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Nov 20, 2024, 8:35 AM EST - 1 year ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Nov 11, 2024, 8:15 AM EST - 1 year ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Nov 7, 2024, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 16, 2024, 8:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aug 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Jul 1, 2024, 4:20 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 28, 2024, 9:20 AM EDT - 1 year ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

May 14, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

May 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Aptevo Therapeutics Provides Pipeline Update

Apr 10, 2024, 9:00 AM EDT - 1 year ago

Aptevo Therapeutics Provides Pipeline Update

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Mar 18, 2024, 6:00 AM EDT - 1 year ago

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Mar 5, 2024, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Traildog19
Traildog19 Dec. 5 at 2:57 AM
$APVO
0 · Reply
th3_fail_k1ng
th3_fail_k1ng Dec. 5 at 12:47 AM
$APVO
0 · Reply
_MANDALORIAN_
_MANDALORIAN_ Dec. 5 at 12:01 AM
$APVO didnt i tell you THIS under 1.1x WAS GOLD?
0 · Reply
ParabolicUptrends
ParabolicUptrends Dec. 4 at 8:52 PM
Micro float SNSE is getting a lot of attention! Could be the next crazy runner! Never chase those big runners that are up 100%+ .. Easy way to lose! Key is to buy early before the runs happen! 💎 These tiny float tickers are running 100-400% recently! SNSE starting to get discovered and trending on Stocktwits! Only 500k shares outstanding - keep it on watch bulls! $LASE $APVO $PBM $RAYA now
0 · Reply
Icansee
Icansee Dec. 4 at 8:49 PM
$APVO
0 · Reply
pandapanic
pandapanic Dec. 4 at 6:38 PM
$APVO soon 😁😁
0 · Reply
Felixii
Felixii Dec. 4 at 3:40 PM
$APVO
0 · Reply
hegdaom
hegdaom Dec. 4 at 2:33 AM
$CAPR $APVO
0 · Reply
DonZulu
DonZulu Dec. 4 at 2:21 AM
$CAPR $APVO My winners
0 · Reply
pandapanic
pandapanic Dec. 3 at 9:26 PM
$APVO for those who keep asking
0 · Reply
th3_fail_k1ng
th3_fail_k1ng Dec. 3 at 9:20 PM
$APVO
0 · Reply
ShadowSnake
ShadowSnake Dec. 3 at 9:19 PM
$APVO any upcoming catalyst?
1 · Reply
Investerare_SAAB
Investerare_SAAB Dec. 3 at 7:29 PM
$APVO 100% soon?
1 · Reply
JarradM8
JarradM8 Dec. 3 at 6:13 PM
$APVO unlikely to see sellers over the next couple of days with data coming up
0 · Reply
Smug_Vortex
Smug_Vortex Dec. 3 at 6:06 PM
$NCNA $APVO Low volume, but it’s mainly all buying. Steady upward trend. Smart long plays. ⬆️
0 · Reply
AlwaysBullish99
AlwaysBullish99 Dec. 3 at 5:31 PM
$APVO APVO has a promising drug but their funding will only last to the end of 2026
0 · Reply
sjl03
sjl03 Dec. 3 at 5:26 PM
$APVO someone convince me to buy this. Anyone here done due diligence on this?
0 · Reply
patrickkallie
patrickkallie Dec. 3 at 12:12 PM
$APVO How much are yall paid to promote this crap? lol
0 · Reply
patrickkallie
patrickkallie Dec. 3 at 12:11 PM
$APVO
0 · Reply
th3_fail_k1ng
th3_fail_k1ng Dec. 2 at 8:27 PM
$APVO
0 · Reply
JBRUN
JBRUN Dec. 2 at 6:42 PM
$APVO
1 · Reply
Investerare_SAAB
Investerare_SAAB Dec. 2 at 6:00 PM
$APVO when it will be published?
0 · Reply